CorMedix (CRMD) Competitors

$8.42 +0.13 (+1.57%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$8.39 -0.03 (-0.36%)

As of 07/17/2026 07:54 PM Eastern

CRMD vs. KLRA, KOD, TRVI, SLS, and TARS

Should you buy CorMedix stock or one of its competitors? MarketBeat compares CorMedix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CorMedix include Kailera Therapeutics (KLRA), Kodiak Sciences (KOD), Trevi Therapeutics (TRVI), SELLAS Life Sciences Group (SLS), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry.

How does CorMedix compare to Kailera Therapeutics?

CorMedix (NASDAQ:CRMD) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

In the previous week, Kailera Therapeutics had 3 more articles in the media than CorMedix. MarketBeat recorded 3 mentions for Kailera Therapeutics and 0 mentions for CorMedix. Kailera Therapeutics' average media sentiment score of 0.32 beat CorMedix's score of 0.00 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Neutral
Kailera Therapeutics	Neutral

CorMedix presently has a consensus target price of $14.86, indicating a potential upside of 76.45%. Kailera Therapeutics has a consensus target price of $42.75, indicating a potential upside of 130.46%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

CorMedix has higher revenue and earnings than Kailera Therapeutics. Kailera Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.12	$163.05M	$2.13	3.95
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A

CorMedix has a net margin of 45.25% compared to Kailera Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Kailera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Kailera Therapeutics	N/A	N/A	N/A

34.2% of CorMedix shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

CorMedix beats Kailera Therapeutics on 9 of the 14 factors compared between the two stocks.

How does CorMedix compare to Kodiak Sciences?

CorMedix (NASDAQ:CRMD) and Kodiak Sciences (NASDAQ:KOD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

CorMedix has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.12	$163.05M	$2.13	3.95
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A

CorMedix has a net margin of 45.25% compared to Kodiak Sciences' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Kodiak Sciences	N/A	-253.85%	-81.48%

CorMedix currently has a consensus price target of $14.86, indicating a potential upside of 76.45%. Kodiak Sciences has a consensus price target of $42.14, indicating a potential downside of 1.17%. Given CorMedix's stronger consensus rating and higher possible upside, analysts clearly believe CorMedix is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

CorMedix has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market. Comparatively, Kodiak Sciences has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market.

In the previous week, Kodiak Sciences had 2 more articles in the media than CorMedix. MarketBeat recorded 2 mentions for Kodiak Sciences and 0 mentions for CorMedix. Kodiak Sciences' average media sentiment score of 0.84 beat CorMedix's score of 0.00 indicating that Kodiak Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Neutral
Kodiak Sciences	Positive

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Comparatively, 44.4% of Kodiak Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

CorMedix beats Kodiak Sciences on 9 of the 14 factors compared between the two stocks.

How does CorMedix compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Trevi Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, CorMedix has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

CorMedix has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
CorMedix	$311.71M	2.12	$163.05M	$2.13	3.95

In the previous week, Trevi Therapeutics had 8 more articles in the media than CorMedix. MarketBeat recorded 8 mentions for Trevi Therapeutics and 0 mentions for CorMedix. Trevi Therapeutics' average media sentiment score of 0.75 beat CorMedix's score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Trevi Therapeutics	Positive
CorMedix	Neutral

Trevi Therapeutics presently has a consensus target price of $22.67, indicating a potential upside of 18.86%. CorMedix has a consensus target price of $14.86, indicating a potential upside of 76.45%. Given CorMedix's higher possible upside, analysts clearly believe CorMedix is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 18.3% of Trevi Therapeutics shares are owned by company insiders. Comparatively, 3.5% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CorMedix has a net margin of 45.25% compared to Trevi Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
CorMedix	45.25%	45.57%	24.76%

Summary

CorMedix beats Trevi Therapeutics on 9 of the 16 factors compared between the two stocks.

How does CorMedix compare to SELLAS Life Sciences Group?

SELLAS Life Sciences Group (NASDAQ:SLS) and CorMedix (NASDAQ:CRMD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

SELLAS Life Sciences Group has a beta of 2.42, meaning that its share price is 142% more volatile than the broader market. Comparatively, CorMedix has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

CorMedix has a net margin of 45.25% compared to SELLAS Life Sciences Group's net margin of 0.00%. CorMedix's return on equity of 45.57% beat SELLAS Life Sciences Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SELLAS Life Sciences Group	N/A	-47.12%	-42.63%
CorMedix	45.25%	45.57%	24.76%

17.4% of SELLAS Life Sciences Group shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 1.3% of SELLAS Life Sciences Group shares are held by company insiders. Comparatively, 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SELLAS Life Sciences Group currently has a consensus target price of $10.00, indicating a potential downside of 24.18%. CorMedix has a consensus target price of $14.86, indicating a potential upside of 76.45%. Given CorMedix's stronger consensus rating and higher probable upside, analysts plainly believe CorMedix is more favorable than SELLAS Life Sciences Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SELLAS Life Sciences Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

CorMedix has higher revenue and earnings than SELLAS Life Sciences Group. SELLAS Life Sciences Group is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SELLAS Life Sciences Group	N/A	N/A	-$26.86M	-$0.23	N/A
CorMedix	$311.71M	2.12	$163.05M	$2.13	3.95

In the previous week, SELLAS Life Sciences Group had 11 more articles in the media than CorMedix. MarketBeat recorded 11 mentions for SELLAS Life Sciences Group and 0 mentions for CorMedix. SELLAS Life Sciences Group's average media sentiment score of 0.98 beat CorMedix's score of 0.00 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media.

Company	Overall Sentiment
SELLAS Life Sciences Group	Positive
CorMedix	Neutral

Summary

CorMedix beats SELLAS Life Sciences Group on 12 of the 15 factors compared between the two stocks.

How does CorMedix compare to Tarsus Pharmaceuticals?

CorMedix (NASDAQ:CRMD) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

CorMedix has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Tarsus Pharmaceuticals has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market.

CorMedix has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.12	$163.05M	$2.13	3.95
Tarsus Pharmaceuticals	$535.08M	4.81	-$66.42M	-$1.14	N/A

CorMedix presently has a consensus price target of $14.86, suggesting a potential upside of 76.45%. Tarsus Pharmaceuticals has a consensus price target of $90.67, suggesting a potential upside of 51.49%. Given CorMedix's higher possible upside, research analysts plainly believe CorMedix is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

34.2% of CorMedix shares are held by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CorMedix has a net margin of 45.25% compared to Tarsus Pharmaceuticals' net margin of -9.02%. CorMedix's return on equity of 45.57% beat Tarsus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%

In the previous week, Tarsus Pharmaceuticals had 8 more articles in the media than CorMedix. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 0 mentions for CorMedix. Tarsus Pharmaceuticals' average media sentiment score of 0.13 beat CorMedix's score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Neutral
Tarsus Pharmaceuticals	Neutral

Summary

CorMedix beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get CorMedix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRMD vs. The Competition

Export

Metric	CorMedix	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$660.57M	$3.69B	$6.87B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	3.95	21.03	27.25	23.92
Price / Sales	2.12	172.02	492.88	72.75
Price / Cash	4.12	154.08	52.99	60.41
Price / Book	1.64	8.26	10.69	6.18
Net Income	$163.05M	$23.83M	$3.59B	$332.29M
7 Day Performance	0.24%	-3.47%	-2.20%	-2.05%
1 Month Performance	-2.88%	2.69%	1.63%	-2.18%
1 Year Performance	-22.47%	45.93%	25.64%	17.67%

CorMedix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRMD CorMedix	2.5081 of 5 stars	$8.42 +1.6%	$14.86 +76.5%	-22.5%	$660.57M	$311.71M	3.95	30
KLRA Kailera Therapeutics	3.8557 of 5 stars	$19.97 -3.4%	$42.75 +114.1%	N/A	$2.59B	N/A	N/A	145	News Coverage Short Interest Increase
KOD Kodiak Sciences	0.8194 of 5 stars	$41.10 -0.5%	$42.14 +2.5%	+672.5%	$2.59B	N/A	N/A	90	News Coverage Gap Down
TRVI Trevi Therapeutics	2.7237 of 5 stars	$16.52 -7.4%	$22.67 +37.2%	+178.0%	$2.53B	N/A	N/A	20	News Coverage Options Volume
SLS SELLAS Life Sciences Group	1.0208 of 5 stars	$12.62 -1.1%	$10.00 -20.8%	+645.2%	$2.51B	N/A	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRMD) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CorMedix (CRMD) Competitors

CRMD vs. KLRA, KOD, TRVI, SLS, and TARS

How does CorMedix compare to Kailera Therapeutics?

Summary

How does CorMedix compare to Kodiak Sciences?

Summary

How does CorMedix compare to Trevi Therapeutics?

Summary

How does CorMedix compare to SELLAS Life Sciences Group?

Summary

How does CorMedix compare to Tarsus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CorMedix (CRMD) Competitors

CRMD vs. KLRA, KOD, TRVI, SLS, and TARS

How does CorMedix compare to Kailera Therapeutics?

Does the media refer more to CRMD or KLRA?

Do analysts recommend CRMD or KLRA?

Which has better earnings & valuation, CRMD or KLRA?

Is CRMD or KLRA more profitable?

Do institutionals & insiders believe in CRMD or KLRA?

Summary

How does CorMedix compare to Kodiak Sciences?

Which has higher valuation & earnings, CRMD or KOD?

Is CRMD or KOD more profitable?

Do analysts recommend CRMD or KOD?

Which has more volatility and risk, CRMD or KOD?

Does the media favor CRMD or KOD?

Do insiders & institutionals believe in CRMD or KOD?

Summary

How does CorMedix compare to Trevi Therapeutics?

Which has more volatility and risk, TRVI or CRMD?

Which has preferable valuation & earnings, TRVI or CRMD?

Does the media prefer TRVI or CRMD?

Do analysts recommend TRVI or CRMD?

Do institutionals and insiders have more ownership in TRVI or CRMD?

Is TRVI or CRMD more profitable?

Summary

How does CorMedix compare to SELLAS Life Sciences Group?

Which has more risk & volatility, SLS or CRMD?

Is SLS or CRMD more profitable?

Do insiders & institutionals have more ownership in SLS or CRMD?

Do analysts rate SLS or CRMD?

Which has better valuation & earnings, SLS or CRMD?

Does the media prefer SLS or CRMD?

Summary

How does CorMedix compare to Tarsus Pharmaceuticals?

Which has more volatility & risk, CRMD or TARS?

Which has stronger valuation and earnings, CRMD or TARS?

Do analysts rate CRMD or TARS?

Do institutionals and insiders have more ownership in CRMD or TARS?

Is CRMD or TARS more profitable?

Does the media refer more to CRMD or TARS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools